Glaxo turns to Sidley for new GC

Glaxo turns to Sidley for new GCGlaxoSmithKline (GSK) has hit the US for its new general counsel, hiring Sidley Austin life sciences partner Dan Troy after a seven month search.

Former GSK general counsel Rupert Bondy joined energy company BP in May after announcing his departure in January this year. Troy will start the top job at GSK on 2 September.

Troy has been at Sidley Austin for the past four years, serving as a partner in the life sciences practice as well as in the appellate litigation group. In addition to private practice he has experience of in-house legal work, having been chief counsel for the US Food and Drug Administration (FDA), where he served as a primary liaison to the White House and the US Department of Health and Human Services (HHS).

He served for three years at the FDA, between 2001 and 2004, before joining Sidley Austin.

Troy will report to Andrew Witty, GSK’s chief executive officer. Witty said: “Dan’s wealth of experience in the regulatory legislative area will be of enormous benefit to us, and ultimately to patients.”